Latest Morning Briefing Stories
Journalist Talks Distribution of Opioid Funds — And the Companies Angling for a Piece
KFF Health News senior correspondent Aneri Pattani made the rounds on national and local media in the last two weeks to discuss the opioid settlement funds flowing to state and local governments and her reporting on the topic. Here’s a collection of her appearances.
Trump Official Who OK’d Drugs From Canada Chairs Company Behind Florida’s Import Plan
Alex Azar advanced Canadian drug importation as Donald Trump’s secretary of Health and Human Services. Now he chairs the board of a company managing Florida’s importation program.
Es común que altos funcionarios de ambos partidos dejen el servicio público por trabajos o puestos en juntas directivas, a menudo mejor remunerados, en empresas de las industrias que antes regulaban
Alex Azar’s Unusual Spin Through the Revolving Door
Washington’s infamous revolving door took an unusual turn for former Health and Human Services secretary Alex Azar. Azar spent about a decade with pharmaceutical giant Eli Lilly and Co. before coming to the nation’s capital to lead HHS in the Trump administration. But in September 2020, just a couple of months before former president Donald […]
Journalists Track Medical Device Malfunctions, Opioid Settlement Payments, and Abortion Bans
KFF Health News and California Healthline staffers made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Pacientes con narcolepsia enfrentan una doble pesadilla: escasez de medicamentos y estigma
Se estima que una de cada 2,000 personas en los Estados Unidos vive con narcolepsia (más de 160,000 en todo el país).
Patients With Narcolepsy Face a Dual Nightmare of Medication Shortages and Stigma
It’s been more than a year since the FDA declared a national shortage of Adderall, and it’s affecting more than just patients with ADHD. Those with narcolepsy, a much rarer condition, are often treated with the same medication. Without it, they’re often unable to drive or function as usual.
KFF Health News' 'What the Health?': 2023 Is a Wrap
2023 was another busy year in health care. As the covid-19 pandemic waned, policymakers looked anew at long-standing obstacles to obtaining and paying for care in the nation’s health care system. Meanwhile, abortion has continued to be an issue in much of the nation, as states respond to the Supreme Court’s 2022 decision overturning the constitutional right to the procedure. This week, Rachel Cohrs of Stat, Sandhya Raman of CQ Roll Call, and Joanne Kenen of Johns Hopkins University and Politico Magazine join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and wrap up the year in health. Also this week, Rovner interviews KFF Health News’ Jordan Rau about his joint KFF Health News-New York Times series “Dying Broke.”
The Year in Opioid Settlements: 5 Things You Need to Know
In the past year, opioid settlement money has gone from an emerging funding stream for which people had lofty but uncertain aspirations to a coveted pot of billions being invested in remediation efforts. Here are some important and evolving factors to watch going forward.
A New Test Could Save Arthritis Patients Time, Money, and Pain. But Will It Be Used?
Stories of chronic pain, drug-hopping, and insurance meddling are all too common among patients with rheumatoid arthritis. Precision medicine offers new hope.
The Market for Biosimilars Is Funky. The Industry Thinks PBMs Are To Blame
Over the past year there’s been movement to rein in the three big PBMs, which face little regulation though they help set drug prices and drug choices for 80 percent of Americans and their doctors. The House voted Dec. 11, 320-71, for legislation that would require the PBMs to change some of the ways they […]
Millions of Dollars Flow From Pharma to Patient Advocacy Groups
Pharma money is all over the place — in universities, companies doing continuing medical education for doctors and in prominent patient advocacy organizations that are household names across America. Public Citizen, a consumer advocacy nonprofit, reports today that between 2010 and 2022, the drug industry’s main lobbying group and member companies provided at least $6 […]
Colorado culpa a Biden y a farmacéuticas por retrasar importaciones de medicamentos de Canadá
Los consumidores estadounidenses pagan algunos de los precios más altos del mundo por medicamentos de marca. En Canadá, el gobierno controla los precios.
Programas ponen los medicamentos sin usar en manos de pacientes que los necesitan
Recogen de centros de salud, residentes, farmacias o prisiones los medicamentos sin abrir y sin caducar que se acumulan cuando los pacientes son dados de alta, cambian de medicina o mueren, y los redistribuyen a pacientes vulnerables.
Colorado Blames Biden Team and Drugmakers for Delaying Canadian Imports
Colorado officials say they haven’t been able to stand up a program to import drugs from Canada because of drugmaker opposition — and the Biden administration’s inaction.
Readers Slam Hospital Monopolies and Blame the Feds for Understaffed Nursing Homes
KFF Health News gives readers a chance to comment on a recent batch of stories.
These Programs Put Unused Prescription Drugs in the Hands of Patients in Need
States and counties look to expand programs that accept donations of unused surplus drugs from places like nursing homes and hospitals and redistribute them to low-income and uninsured residents.
Watch and Listen: Opioid Settlement Case Triggers Protests Outside the High Court
The Supreme Court heard arguments over whether the Sacklers, the family behind Purdue Pharma — which marketed OxyContin — could claim immunity from future lawsuits without claiming bankruptcy.
Colorado Says Drug Industry Blocked Its Canada Dreams – And Biden Hasn’t Helped
Colorado’s leaders had grand plans to import cheaper medicines from Canada, after the Trump administration issued rules in 2020 allowing states to try it. But officials in Denver say they’ve been stymied by opposition from drugmakers — as well as the Biden administration’s inaction on the policy. That’s according to a Dec. 1 report we […]
Many Autoimmune Disease Patients Struggle With Diagnosis, Costs, Inattentive Care
Despite the prevalence of autoimmune conditions, like the thyroid disease Hashimoto’s, sometimes finding help can prove frustrating as well as expensive. There are often no definitive diagnostic tests, so patients may rack up big bills as they search for confirmation of their condition and for treatment options.
